Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Heart Rhythm. 2012 Aug 28;9(12):2034–2041. doi: 10.1016/j.hrthm.2012.08.026

Figure 5. CaMKII inhibition normalizes ankyrin-B+/− arrhythmia phenotypes.

Figure 5

A) Representative ECG recordings from wild-type, ankyrin-B+/−, AC3I, and ankyrin-B+/− X AC3I mice at baseline and following exercise and treatment with adrenergic agonist. Center recording for ankyrin-B+/− mouse illustrates typical example of arrhythmia lasting minutes from this mouse model. B) Incidence of sustained ventricular arrhythmia in wild-type, ankyrin-B+/−, AC3I, and ankyrin-B+/− X AC3I mice following exercise and treatment with β-adrenergic agonist. In panel B, # denotes p<0.05 for ankyrin-B+/− mice vs. wild-type mice and Δ denotes p<0.05 for ankyrin-B+/− mice vs. ankyrin-B+/− X AC3I mice. C) Survival of wild-type, ankyrin-B+/−, AC3I, and ankyrin-B+/− X AC3I mice following exercise and treatment with adrenergic agonist. In panel C, * denotes p<0.05 of ankyrin-B+/− vs. wild-type mice. For B-C, N values are listed in panels.